122 related articles for article (PubMed ID: 26797585)
1. Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer.
Chedgy EC; Annala M; Beja K; Warner EW; Gleave ME; Chi KN; Wyatt AW
Clin Genitourin Cancer; 2016 Apr; 14(2):e233-6. PubMed ID: 26797585
[No Abstract] [Full Text] [Related]
2. DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
Zhu S; Zhang Z; Zhang H; Liu Z; Liu M; Liu Q; Zang L; Wang L; Ji J; Wu B; Sun L; Zhang Z; Cao H; Wang Y; Wang H; Shang Z; Niu Y
Prostate; 2022 Mar; 82(4):464-474. PubMed ID: 35037281
[TBL] [Abstract][Full Text] [Related]
3. A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.
Kosaka T; Hongo H; Aimono E; Matsumoto K; Hayashida T; Mikami S; Nishihara H; Oya M
Pathol Int; 2019 Dec; 69(12):715-720. PubMed ID: 31631483
[TBL] [Abstract][Full Text] [Related]
4. [A rare case of large cell neuroendocrine carcinoma of the thymus].
Haga T; Nakajima Y; Kitamura A; Kuroda F; Takiguchi Y; Tatsumi K
Nihon Kokyuki Gakkai Zasshi; 2010 Oct; 48(10):755-8. PubMed ID: 21066864
[TBL] [Abstract][Full Text] [Related]
5. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center.
Sharabi A; Kim SS; Kato S; Sanders PD; Patel SP; Sanghvi P; Weihe E; Kurzrock R
Oncologist; 2017 Jun; 22(6):631-637. PubMed ID: 28550027
[TBL] [Abstract][Full Text] [Related]
6. [Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].
Campedel L; Kossaï M; Blanc-Durand P; Rouprêt M; Seisen T; Compérat E; Spano JP; Malouf G
Bull Cancer; 2017 Sep; 104(9):789-799. PubMed ID: 28673439
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous metastases of prostatic small cell neuroendocrine carcinoma.
Nakamura Y; Kashiwagi K; Nakamura A; Muto M
Eur J Dermatol; 2014; 24(5):620-2. PubMed ID: 25075810
[No Abstract] [Full Text] [Related]
8. Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation.
Steinberger AE; Cotogno P; Ledet EM; Lewis B; Sartor O
Clin Genitourin Cancer; 2017 Feb; 15(1):e69-e71. PubMed ID: 27726949
[No Abstract] [Full Text] [Related]
9. Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma.
Bajetta E; Catena L; Biondani P; Pusceddu S; Valente M; Bianco N; Novelli E
Anticancer Res; 2014 Oct; 34(10):5657-60. PubMed ID: 25275070
[TBL] [Abstract][Full Text] [Related]
10. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B; Drost R; Schut E; de Bruin M; van der Burg E; Derksen PW; Holstege H; Liu X; van Drunen E; Beverloo HB; Smith GC; Martin NM; Lau A; O'Connor MJ; Jonkers J
Clin Cancer Res; 2008 Jun; 14(12):3916-25. PubMed ID: 18559613
[TBL] [Abstract][Full Text] [Related]
12. [A case of gastric large cell neuroendocrine carcinoma (LCNEC) for whom chemotherapy of CDDP+CPT-11 proved very effective].
Kirii Y; Ichikawa C; Miyamoto M; Hata M; Miyairi J; Takagi H; Fukushima M; Ota H
Gan To Kagaku Ryoho; 2010 May; 37(5):895-8. PubMed ID: 20495323
[TBL] [Abstract][Full Text] [Related]
13. A Case of Duodenal Neuroendocrine Carcinoma Treated with Amrubicin as Second-line Chemotherapy.
Inoue T; Sano H; Mizushima T; Nishie H; Iwasaki H; Okumura F
J Gastrointestin Liver Dis; 2015 Sep; 24(3):379-82. PubMed ID: 26405711
[TBL] [Abstract][Full Text] [Related]
14. Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung.
Yoshida H; Sekine I; Tsuta K; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
Jpn J Clin Oncol; 2011 Jul; 41(7):897-901. PubMed ID: 21636606
[TBL] [Abstract][Full Text] [Related]
15. Selective Actionable and Druggable Protein Kinases Drive the Progression of Neuroendocrine Prostate Cancer.
Lu C; Qie Y; Liu S; Wu C; Zhang Z; Liu R; Yang K; Hu H; Xu Y
DNA Cell Biol; 2018 Sep; 37(9):758-766. PubMed ID: 29969286
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of the effectiveness of cisplatin in the treatment of disseminated cancer of the prostate].
Nogueira March JL; Ojea A; Jamardo D; Díez E; Figueiredo L
Arch Esp Urol; 1985; 38(1):28-34. PubMed ID: 4039554
[No Abstract] [Full Text] [Related]
17. Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy.
Azad AA; Jones EC; Chi KN
Clin Genitourin Cancer; 2014 Aug; 12(4):e151-3. PubMed ID: 24787970
[No Abstract] [Full Text] [Related]
18. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
[TBL] [Abstract][Full Text] [Related]
19.
Symonds L; Konnick E; Vakar-Lopez F; Cheng HH; Schweizer MT; Nelson PS; Pritchard CC; Montgomery B
JCO Precis Oncol; 2022 Jul; 6():e2200091. PubMed ID: 35834759
[No Abstract] [Full Text] [Related]
20. KIT as a therapeutic target in neuroendocrine prostate cancer.
Azad AA; Kostos L; Agarwal N
Cancer Cell; 2022 Nov; 40(11):1266-1268. PubMed ID: 36332623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
